title: Protective effect of desferrioxamin against TPA caused inflammation in CD-1 mouse skin.
abstract: This study was planned to investigate the possible inhibitory effect of the oxygen radical scavenger agent desferrioxamin on 12-0-tetradecanoylphorbol-13-acetate (TPA) induced oedema and hyperplasia in the skin of 119 CD-1 mice. Topical application of different doses of desferrioxamin (20 ng, 200 ng, 2 microg, 20 microg and 200 microg per mouse) 10 min prior to 1 nmol TPA, inhibited oedema of mouse ears significantly (P < 0.02-0.001) except with the doses of 200 ng and 20 ng/mouse. The inhibitory effect of desferrioxamin (2 mg/mouse) in TPA induced mouse skin hyperplasia was also investigated in four groups of 20 CD-1 mice. Desferrioxamin produced an 83.7% reduction in epidermal thickness (P<0.0001) and an 85.8% reduction in the number of vertical cell layers (P <0.0001). Data also indicated the inhibitory effect of desferrioxamin against TPA caused infiltration of neutrophiles (P <0.02). These results suggest that the free oxygen radical scavenger agent desferrioxamin has a chemopreventive effect against TPA induced inflammation and hyperplasia.
authors.affiliation: Department of Surgery, Taksim State Hospital, Istanbul, Turkey.
authors.forename: G R
authors.initials: GR
authors.lastname: Soybir
authors.forename: H
authors.initials: H
authors.lastname: Koyuncu
authors.forename: F
authors.initials: F
authors.lastname: Köksoy
authors.forename: O
authors.initials: O
authors.lastname: Yalçin
authors.forename: A
authors.initials: A
authors.lastname: Ozşeker
authors.forename: C
authors.initials: C
authors.lastname: Alatli
authors.forename: C
authors.initials: C
authors.lastname: Topuzlu
mesh_terms: D000287:Administration, Topical; D000818:Animals; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D003872:Dermatitis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006965:Hyperplasia / Q000139:chemically induced / Q000517:prevention & control; D051379:Mice; D008815:Mice, Inbred Strains; D012016:Reference Values; D017262:Siderophores / Q000008:administration & dosage / Q000627:therapeutic use*; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives
chemical_list: D017262:Siderophores; C032975:12-O-tetradeca-2,4,6,8-tetranoylphorbol-13-acetate; D003676:Deferoxamine; D013755:Tetradecanoylphorbol Acetate